Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), School of Medicine, Shanghai University, Nantong 226011, China; Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai 200444, China.
Department of Cardiology, Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200090, China.
EBioMedicine. 2022 Jul;81:104108. doi: 10.1016/j.ebiom.2022.104108. Epub 2022 Jun 22.
Pathological cardiac hypertrophy occurs in response to numerous stimuli and precedes heart failure (HF). Therapies that ameliorate pathological cardiac hypertrophy are highly needed.
The expression level of miR-30d was analyzed in hypertrophy models and serum of patients with chronic heart failure by qRT-PCR. Gain and loss-of-function experiments of miR-30d were performed in vitro. miR-30d gain of function were performed in vivo. Bioinformatics, western blot, luciferase assay, qRT-PCR, and immunofluorescence were performed to examine the molecular mechanisms of miR-30d.
miR-30d was decreased in both murine and neonatal rat cardiomyocytes (NRCMs) models of hypertrophy. miR-30d overexpression ameliorated phenylephrine (PE) and angiotensin II (Ang II) induced hypertrophy in NRCMs, whereas the opposite phenotype was observed when miR-30d was downregulated. Consistently, the miR-30d transgenic rat was found to protect against isoproterenol (ISO)-induced pathological hypertrophy. Mechanistically, methyltransferase EZH2 could promote H3K27me3 methylation in the promotor region of miR-30d and suppress its expression during the pathological cardiac hypertrophy. miR-30d prevented pathological cardiac hypertrophy via negatively regulating its target genes MAP4K4 and GRP78 and inhibiting pro-hypertrophic nuclear factor of activated T cells (NFAT). Adeno-associated virus (AAV) serotype 9 mediated-miR-30d overexpression exhibited beneficial effects in murine hypertrophic model. Notably, miR-30d was reduced in serum of patients with chronic heart failure and miR-30d overexpression could significantly ameliorate pathological hypertrophy in human embryonic stem cell-derived cardiomyocytes.
Overexpression of miR-30d may be a potential approach to treat pathological cardiac hypertrophy.
This work was supported by the grants from National Key Research and Development Project (2018YFE0113500 to J Xiao), National Natural Science Foundation of China (82020108002 to J Xiao, 81900359 to J Li), the grant from Science and Technology Commission of Shanghai Municipality (20DZ2255400 and 21XD1421300 to J Xiao, 22010500200 to J Li), Shanghai Sailing Program (19YF1416400 to J Li), the "Dawn" Program of Shanghai Education Commission (19SG34 to J Xiao), the "Chen Guang" project supported by the Shanghai Municipal Education Commission and Shanghai Education Development Foundation (19CG45 to J Li).
病理性心肌肥厚是对多种刺激的反应,发生在心力衰竭(HF)之前。急需改善病理性心肌肥厚的治疗方法。
通过 qRT-PCR 分析肥厚模型和慢性心力衰竭患者血清中的 miR-30d 表达水平。在体外进行 miR-30d 的增益和功能丧失实验。在体内进行 miR-30d 的功能获得实验。进行生物信息学、western blot、荧光素酶测定、qRT-PCR 和免疫荧光实验以检验 miR-30d 的分子机制。
在肥大的鼠和新生大鼠心肌细胞(NRCM)模型中,miR-30d 的表达均降低。miR-30d 的过表达可改善去甲肾上腺素(PE)和血管紧张素 II(Ang II)诱导的 NRCM 肥大,而当 miR-30d 下调时则观察到相反的表型。同样,发现 miR-30d 转基因大鼠可预防异丙肾上腺素(ISO)诱导的病理性心肌肥厚。在机制上,甲基转移酶 EZH2 可以促进 miR-30d 启动子区域的 H3K27me3 甲基化,并在病理性心肌肥厚过程中抑制其表达。miR-30d 通过负调控其靶基因 MAP4K4 和 GRP78 并抑制促肥大激活 T 细胞核因子(NFAT)来预防病理性心肌肥厚。腺相关病毒(AAV)血清型 9 介导的 miR-30d 过表达在鼠肥厚模型中表现出有益的效果。值得注意的是,miR-30d 在慢性心力衰竭患者的血清中减少,miR-30d 的过表达可显著改善人胚胎干细胞衍生的心肌细胞中的病理性肥大。
miR-30d 的过表达可能是治疗病理性心肌肥厚的一种有潜力的方法。
本研究得到国家重点研发计划(2018YFE0113500 至 J Xiao)、国家自然科学基金(82020108002 至 J Xiao,81900359 至 J Li)、上海市科学技术委员会(20DZ2255400 和 21XD1421300 至 J Xiao,22010500200 至 J Li)、上海扬帆计划(19YF1416400 至 J Li)、上海教育委员会“曙光计划”(19SG34 至 J Xiao)、上海市教育委员会和上海市教育发展基金会“晨光计划”(19CG45 至 J Li)的资助。